335 related articles for article (PubMed ID: 25531328)
1. Loss of ATF3 promotes Akt activation and prostate cancer development in a Pten knockout mouse model.
Wang Z; Xu D; Ding HF; Kim J; Zhang J; Hai T; Yan C
Oncogene; 2015 Sep; 34(38):4975-84. PubMed ID: 25531328
[TBL] [Abstract][Full Text] [Related]
2. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Tan M; Xu J; Siddiqui J; Feng F; Sun Y
Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
[TBL] [Abstract][Full Text] [Related]
3. Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis.
Zhong C; Saribekyan G; Liao CP; Cohen MB; Roy-Burman P
Cancer Res; 2006 Feb; 66(4):2188-94. PubMed ID: 16489020
[TBL] [Abstract][Full Text] [Related]
4. Pten null prostate tumorigenesis and AKT activation are blocked by targeted knockout of ER chaperone GRP78/BiP in prostate epithelium.
Fu Y; Wey S; Wang M; Ye R; Liao CP; Roy-Burman P; Lee AS
Proc Natl Acad Sci U S A; 2008 Dec; 105(49):19444-9. PubMed ID: 19033462
[TBL] [Abstract][Full Text] [Related]
5. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
Blando J; Portis M; Benavides F; Alexander A; Mills G; Dave B; Conti CJ; Kim J; Walker CL
Am J Pathol; 2009 May; 174(5):1869-79. PubMed ID: 19395652
[TBL] [Abstract][Full Text] [Related]
6. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.
Conley-LaComb MK; Saliganan A; Kandagatla P; Chen YQ; Cher ML; Chinni SR
Mol Cancer; 2013 Jul; 12(1):85. PubMed ID: 23902739
[TBL] [Abstract][Full Text] [Related]
7. Gata3 antagonizes cancer progression in Pten-deficient prostates.
Nguyen AH; Tremblay M; Haigh K; Koumakpayi IH; Paquet M; Pandolfi PP; Mes-Masson AM; Saad F; Haigh JJ; Bouchard M
Hum Mol Genet; 2013 Jun; 22(12):2400-10. PubMed ID: 23428429
[TBL] [Abstract][Full Text] [Related]
8. PTEN loss-mediated Akt activation increases the properties of cancer stem-like cell populations in prostate cancer.
Kim RJ; Bae E; Hong YK; Hong JY; Kim NK; Ahn HJ; Oh JJ; Park DS
Oncology; 2014; 87(5):270-9. PubMed ID: 25139413
[TBL] [Abstract][Full Text] [Related]
9. KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis.
Li G; Kanagasabai T; Lu W; Zou MR; Zhang SM; Celada SI; Izban MG; Liu Q; Lu T; Ballard BR; Zhou X; Adunyah SE; Matusik RJ; Yan Q; Chen Z
Cancer Res; 2020 Nov; 80(21):4633-4643. PubMed ID: 32868382
[TBL] [Abstract][Full Text] [Related]
10. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
[TBL] [Abstract][Full Text] [Related]
11. KLF5 inhibits angiogenesis in PTEN-deficient prostate cancer by attenuating AKT activation and subsequent HIF1α accumulation.
Ci X; Xing C; Zhang B; Zhang Z; Ni JJ; Zhou W; Dong JT
Mol Cancer; 2015 Apr; 14():91. PubMed ID: 25896712
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer.
Wu Z; He B; He J; Mao X
Prostate; 2013 May; 73(6):596-604. PubMed ID: 23060044
[TBL] [Abstract][Full Text] [Related]
13. Posttranslational regulation of membrane type 1-matrix metalloproteinase (MT1-MMP) in mouse PTEN null prostate cancer cells: Enhanced surface expression and differential O-glycosylation of MT1-MMP.
Kim S; Huang W; Mottillo EP; Sohail A; Ham YA; Conley-Lacomb MK; Kim CJ; Tzivion G; Kim HR; Wang S; Chen YQ; Fridman R
Biochim Biophys Acta; 2010 Nov; 1803(11):1287-97. PubMed ID: 20620173
[TBL] [Abstract][Full Text] [Related]
14. Timp3 loss accelerates tumour invasion and increases prostate inflammation in a mouse model of prostate cancer.
Adissu HA; McKerlie C; Di Grappa M; Waterhouse P; Xu Q; Fang H; Khokha R; Wood GA
Prostate; 2015 Dec; 75(16):1831-43. PubMed ID: 26332574
[TBL] [Abstract][Full Text] [Related]
15. Methylseleninic Acid Superactivates p53-Senescence Cancer Progression Barrier in Prostate Lesions of Pten-Knockout Mouse.
Wang L; Guo X; Wang J; Jiang C; Bosland MC; Lü J; Deng Y
Cancer Prev Res (Phila); 2016 Jan; 9(1):35-42. PubMed ID: 26511486
[TBL] [Abstract][Full Text] [Related]
16. CXCR4 and PTEN are involved in the anti-metastatic regulation of anethole in DU145 prostate cancer cells.
Rhee YH; Chung PS; Kim SH; Ahn JC
Biochem Biophys Res Commun; 2014 May; 447(4):557-62. PubMed ID: 24525130
[TBL] [Abstract][Full Text] [Related]
17. Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model.
Shukla S; Maclennan GT; Marengo SR; Resnick MI; Gupta S
Prostate; 2005 Aug; 64(3):224-39. PubMed ID: 15712212
[TBL] [Abstract][Full Text] [Related]
18. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J
Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465
[TBL] [Abstract][Full Text] [Related]
19. NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence.
Manda KR; Tripathi P; Hsi AC; Ning J; Ruzinova MB; Liapis H; Bailey M; Zhang H; Maher CA; Humphrey PA; Andriole GL; Ding L; You Z; Chen F
Oncogene; 2016 Jun; 35(25):3282-92. PubMed ID: 26477312
[TBL] [Abstract][Full Text] [Related]
20. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss.
Lei Q; Jiao J; Xin L; Chang CJ; Wang S; Gao J; Gleave ME; Witte ON; Liu X; Wu H
Cancer Cell; 2006 May; 9(5):367-78. PubMed ID: 16697957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
